Orally active, species-independent novel A(3) adenosine receptor antagonist protects against kidney injury in db/db mice

Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease, and the current pharmacological treatment for DKD is limited to renin-angiotensin system (RAS) inhibitors. Adenosine is detectable in the kidney and is significantly elevated in response to cellular damage. While all 4 k...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorotea, Debra, Cho, Ahreum, Lee, Gayoung, Kwon, Guideock, Lee, Junghwa, Sahu, Pramod K., Jeong, Lak Shin, Cha, Dae Ryong, Ha, Hunjoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938017/
https://www.ncbi.nlm.nih.gov/pubmed/29674631
http://dx.doi.org/10.1038/s12276-018-0053-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938017/
https://www.ncbi.nlm.nih.gov/pubmed/29674631
http://dx.doi.org/10.1038/s12276-018-0053-x

Ejemplares similares